Sign in
CompletedNo phase

VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)

Key facts

Who runs it
BioMérieux
Where
Detroit, Orlando, Rochester, and St Louis, United StatesSee the 5 sites
Trial code
Status
Completed
People taking part
903 people enrolled
Started
16 May 2024
Ended
12 Nov 2025
Type of study
Interventional
Treatments tested
  • VIDAS® TBI Test [GFAP and UCH-L1 assays]
Record updated
6 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adult subject ≥ 18 years old
  • Subject with a Glasgow Coma Scale (GCS) score between 13-15 on admission
  • Subject presenting to the Emergency Department for suspected mild Traumatic Brain Injury
  • Subject with a non-contrast head Computed Tomography (CT) scan ordered per the clinical site's care usual care
  • Blood sampling possible within 12 hours of injury (1 tube of 4-5 mL of blood)
  • Subject expected to stay at least 2 hours in the ED or in a ward
  • Subject with signed Informed Consent Form (ICF)

Who cannot take part

  • Subject with non-traumatic neurological disorders (e.g, dementia, Parkinson's disease, multiple sclerosis, seizure disorder, brain tumors, spontaneous intracranial haematoma)
  • Neurosurgery, stroke or transient ischemic attack within the last 30 days
  • Subject with an active cancer
  • Time of injury unknown
  • Subject with penetrating head injury
  • Special populations, including women with known pregnancy, prisoners, or institutionalized individuals

Where in United States

  • Wayne State UniversityDetroit, United States
  • Orlando HealthOrlando, United States
  • Mayo ClinicRochester, United States
  • University of RochesterRochester, United States
  • Washington UniversitySt Louis, United States

About the trial

What the trial wants to find out

Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out this unmet needs. The goal of the herein study is to generate real-world data and evidences to support the VIDAS® TBI performances.

The group in the trial

  • Subjects with Mild Traumatic Brain injuryTreatment being tested

    Subjects presenting to the ED within 12 hours of suspected mild head trauma and a Glasgow Score of 13-15 undergo to blood collection for VIDAS® TBI \[GFAP, UCH-L1\] testing.

    Treatment: VIDAS® TBI Test [GFAP and UCH-L1 assays]

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Real-life Performance and Added Value of the VIDAS® TBI Blood Test in the Assessment of Mild Traumatic Brain Injury (mTBI), in Subjects With a Glasgow Coma Scale (GCS) Between 13-15
Record updated
6 March 2026